argatroban

Argatroban is a synthetic, small-molecule direct thrombin inhibitor that reversibly binds to the catalytic active site of thrombin, blocking thrombin-mediated conversion of fibrinogen to fibrin, as well as thrombin-induced activation of factors V, VIII, XIII, protein C, and platelet aggregation. Unlike heparin, it does not require antithrombin III as a cofactor and can inhibit both circulating and clot-bound thrombin, making it effective even in clot-rich environments.

Clinical use: Argatroban is primarily indicated for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT) and for anticoagulation during percutaneous coronary intervention (PCI) in patients with or at risk for HIT. It is administered intravenously with a short half-life (~45 minutes), making it easy to titrate.

Monitoring: Anticoagulant effect is monitored using activated partial thromboplastin time (aPTT), targeting 1.5–3 times baseline.

Metabolism: Unique among DTIs, argatroban is hepatically metabolized (via CYP3A4/5) and excreted in bile, making it the preferred DTI in patients with renal impairment (as opposed to lepirudin or bivalirudin, which are renally cleared).

Key considerations: - No specific reversal agent/antidote exists. - Can falsely elevate INR, complicating the transition to warfarin therapy in HIT patients (bridging therapy requires careful monitoring, often using chromogenic factor X assay). - Avoid in patients with significant hepatic impairment. - Does not cross-react with heparin-induced antibodies, making it safe for use in HIT.

High-yield boards association: Argatroban (and other DTIs like bivalirudin, dabigatran) are classically tested in the context of HIT management, distinguishing them from heparin (which causes HIT) and warfarin (which can cause skin necrosis when started too early in acute HIT due to transient protein C deficiency).